Bionomics Limited, (BNOX): Price and Financial Metrics
BNOX Price/Volume Stats
| Current price | $0.98 | 52-week high | $6.41 |
| Prev. close | $0.98 | 52-week low | $0.87 |
| Day low | $0.96 | Volume | 14,400 |
| Day high | $0.99 | Avg. volume | 200,659 |
| 50-day MA | $1.08 | Dividend yield | N/A |
| 200-day MA | $1.70 | Market Cap | 7.99M |
BNOX Stock Price Chart Interactive Chart >
Bionomics Limited, (BNOX) Company Bio
Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia and the United States. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which has completed phase 2 clinical trial for the treatment of social anxiety disorder and post-traumatic stress disorder. It also develops BNC375, a small molecule therapeutics for the treatment of cognitive impairment in Alzheimer's disease; BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, a vascular disrupting agent, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer, and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. Bionomics Limited has a licensing agreement with Merck & Co., Inc. The company was incorporated in 1996 and is based in Eastwood, Australia.
Latest BNOX News From Around the Web
Below are the latest news stories about BIONOMICS LIMITED that investors may wish to consider to help them evaluate BNOX as an investment opportunity.
Jazz Pharmaceuticals' (JAZZ) PTSD Drug Misses Study GoalsAfter a mid-stage study fails to show any improvement in its primary or secondary endpoints, Jazz (JAZZ) plans to scrap the development of its PTSD drug. |
Bionomics Presents Detailed Data on the Validity and Reliability of the Subjective Units of Distress Scale at the 2023 American College of Neuropsychopharmacology Annual MeetingA psychometric analysis concluded that Subjective Units of Distress Scale (SUDS) is a psychometrically valid, sensitive, and reliable tool for evaluation of social anxiety.SUDS will be used as the primary outcome in future Phase 3 social anxiety disorder (SAD) clinical trials. ADELAIDE, Australia and CAMBRIDGE, Mass., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion c |
12 Best Stocks For Day TradingIn this piece, we will take a look at the 12 Best Stocks For Day Trading. If you want to skip our introduction to trading indicators and the economic climate, then check out 5 Best Stocks For Day Trading. The modern day stock market is significantly different from the one of the early 1900s. These […] |
Bionomics Announces Successful End-of-Phase 2 Meeting with the FDA and Solidifies Plans to Initiate the Registrational Program for BNC210 in Social Anxiety DisorderPositive outcome of End-of-Phase 2 meeting with U.S. Food and Drug Administration (FDA) in September 2023 enables advancement of BNC210 into Phase 3 studies in Social Anxiety DisorderCompany confirms agreement with the FDA on Phase 3 clinical program and alignment on nonclinical toxicology studies required for registrationCompany is on track for first patient dosed in the Phase 3 program planed for Q1’24 ADELAIDE, Australia, and CAMBRIDGE, Mass., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Bionomics Limit |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on MondayPre-market stock movers are worth checking out on Monday as we start off the week with all the latest news this morning! |
BNOX Price Returns
| 1-mo | -2.00% |
| 3-mo | -6.67% |
| 6-mo | -73.37% |
| 1-year | -58.30% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -33.78% |
| 2023 | -68.17% |
| 2022 | -62.95% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...